Success Metrics

Clinical Success Rate
84.0%

Based on 21 completed trials

Completion Rate
84%(21/25)
Active Trials
1(3%)
Results Posted
43%(9 trials)
Terminated
4(14%)

Phase Distribution

Ph not_applicable
4
14%
Ph phase_1
3
10%
Ph phase_2
9
31%
Ph phase_3
10
34%
Ph phase_4
3
10%

Phase Distribution

3

Early Stage

9

Mid Stage

13

Late Stage

Phase Distribution29 total trials
Phase 1Safety & dosage
3(10.3%)
Phase 2Efficacy & side effects
9(31.0%)
Phase 3Large-scale testing
10(34.5%)
Phase 4Post-market surveillance
3(10.3%)
N/ANon-phased studies
4(13.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.8%

21 of 26 finished

Non-Completion Rate

19.2%

5 ended early

Currently Active

1

trials recruiting

Total Trials

29

all time

Status Distribution
Active(1)
Completed(21)
Terminated(5)
Other(2)

Detailed Status

Completed21
Terminated4
unknown2
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
29
Active
1
Success Rate
84.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (10.3%)
Phase 29 (31.0%)
Phase 310 (34.5%)
Phase 43 (10.3%)
N/A4 (13.8%)

Trials by Status

recruiting13%
withdrawn13%
unknown27%
completed2172%
terminated414%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT06120140Phase 2

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Recruiting
NCT05479123Phase 4

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

Terminated
NCT02422017Phase 2

Topical Timolol Benefit in Venous Ulcers

Completed
NCT02390284Phase 3

Stop Retinal Ganglion Cell Dysfunction Study

Terminated
NCT03282981Phase 3

Beta Adrenergic Antagonist for the Healing of Chronic DFU

Completed
NCT00579969Phase 2

Comparison of Latanoprost Vs. Timolol

Terminated
NCT00572936Phase 2

Circadian Rhythms of Aqueous Humor Dynamics in Humans

Completed
NCT02774590Phase 1

Timolol for the Treatment of Acne and Rosacea

Completed
NCT04868175Not Applicable

Interval Intraocular Pressure in Intravitreal Injection Study

Completed
NCT00159653Phase 3

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

Completed
NCT00277498Phase 3

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Completed
NCT00716859Phase 3

A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.

Completed
NCT00751049Phase 3

A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom

Completed
NCT00751062Phase 3

A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia

Completed
NCT03836664Phase 2

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

Completed
NCT01533376Phase 1

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

Terminated
NCT02742649Phase 1

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension

Completed
NCT01749930Phase 3

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Completed
NCT02731287Phase 2

Topical Timolol for Infantile Hemangioma in Early Proliferative Phase

Completed
NCT01749904Phase 3

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Completed

Drug Details

Intervention Type
DRUG
Total Trials
29